NCIPHER-SECURITY
24.1.2019 14:02:03 CET | Business Wire | Press release
nCipher Security , the provider of trust, integrity and control for business critical information and applications, officially launched today creating a new leader in the general purpose hardware security module (HSM) marketplace.
Today’s fast moving digital environment offers opportunities to enhance customer satisfaction, improve operational efficiency and gain competitive advantage, but in doing so also raises new security challenges. nCipher’s market-leading solutions and services allow organizations to keep pace with innovation while protecting their business critical assets from security breaches.
The world’s leading organizations have depended on nCipher nShield HSMs for more than 20 years to provide a root of trust for their business critical applications and meet their cybersecurity needs. Our customers include 5 of the top 10 Fortune 100 and 10 of the top 20 FTSE 100 companies.
Organizations are also now subject to an increasing number of strict compliance mandates such as the EU General Data Protection Regulation (GDPR), California Data Breach Notification Law and Australia Privacy Amendment Act 2017. nCipher provides the highest level of assurance in protecting sensitive data, enabling organizations to meet these very stringent compliance controls.
Cindy Provin, Chief Executive Officer, nCipher Security says:
“I
am both excited and proud to lead an innovative, agile, world-class team
helping our customers as they embrace a digital future. nCipher nShield
HSMs are a critical component in securing today’s business critical
applications as well as the journey to the cloud, new digital payment
methods and the internet of things. With high profile data breaches
hitting the headlines daily and newly enforced legislation,
organizations need to get security right.”
nCipher customers rely on nShield HSMs to provide a root of trust for a wide variety of business applications including public key infrastructures (PKIs), SSL/TLS encryption key protection, code signing, digital signing and blockchain. As growth in the Internet of Things (IoT) creates greater demand for device IDs and certificates, nShield HSMs will continue to support critical security measures such as device authentication using digital certificates.
nCipher highlights:
- World class, committed and experienced leadership team
- Exceptional technology supported by 32 patents
- 700+ years of applied cryptography and security experience
- Strong third party certifications – FIPS 140-2, eIDAS, Common Criteria
- 20-year heritage providing market-leading general purpose HSMs
- Strong installed customer base including 5 of the top 10 Fortune 100 and 10 of the top 20 FTSE 100
- Global network of strategic technology partners and distributors
nCipher Security is now a separate stand-alone business within Thales and held separate from the rest of the Thales Group pending its divestiture to a third party buyer. This results from Thales Group’s offer to acquire Gemalto and the demands of a number of antitrust agencies, including the European Commission , to create a strong player in the general purpose HSM space in order to preserve competition in this important market place and continued supply and innovations to our nShield customers. Thales and Gemalto continue to work constructively with the competent antitrust authorities to obtain the remaining merger control regulatory clearances in Russia and the United States. In addition, Thales and Gemalto are seeking regulatory clearance relating to foreign investments from the competent authority in Russia.
nCipher Security will be exhibiting at RSA Conference 2019 on booth #3106, to learn how our cryptographic solutions guard against today’s threats and attacks, enable compliance and protect your business applications.
Follow us on LinkedIn , Twitter , Facebook and Instagram – search nCipherSecurity.
About nCipher Security
Today’s fast moving digital environment enhances customer satisfaction, gives competitive advantage and improves operational efficiency. It also multiplies the security risks.
nCipher Security, a leader in the general purpose hardware security module (HSM) market, empowers world-leading organizations by delivering trust, integrity and control to their business critical information and applications.
Our cryptographic solutions secure emerging technologies – cloud, IoT, blockchain, digital payments – and help meet new compliance mandates, using the same proven technology that global organizations depend on today to protect against threats to their sensitive data, network communications and enterprise infrastructure. We deliver trust for your business critical applications, ensuring the integrity of your data and putting you in complete control – today, tomorrow, at all times. www.ncipher.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190124005206/en/
Contact:
For more information please contact:
nCipher Security Megan Nemeh megan.nemeh@ncipher.com +1 408 887 5064 Liz Harris liz.harris@ncipher.com +44 7973 973648
US Media Bospar PR PRfornCipher@bospar.com
UK Media Hotwire PR nCipher@hotwireglobal.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom